Effect of FODMAP Restriction on Persistent GI-symptoms in Coeliac Patients
Primary Purpose
Celiac Disease, Irritable Bowel Syndrome, Diet Modification
Status
Unknown status
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Low FODMAP diet
Sponsored by
About this trial
This is an interventional treatment trial for Celiac Disease focused on measuring Celiac disease, Irritable bowel syndrome
Eligibility Criteria
Inclusion Criteria:
- Coeliac disease
- Adherent to GFD for at least 12 months
- Strictly adherent to GFD
- Normal coeliac disease (CD) serology and duodenal biopsy (Marsh 0-1)
- Persistent GI-symptoms defined by GSRS-IBS score of 30 or more
- Living less than 2 hour from study centre
Exclusion Criteria:
- Pregnancy or lactating women
- Use of immunomodulating drugs in the last 3 months
- Use of anti-inflammatory drugs in the last 3 months
- Use of antacid drugs in the last 2 months
- Ongoing infection (mild infection such as upper airway infection is ok)
- Other chronical bowel disorder (except for IBS)
- Previous tried the LFD with guidance of a dietician
Sites / Locations
- Rikshospitalet-Radiumhospitalet HF, Oslo University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
Low FODMAP diet (LFD)
Control
Arm Description
The LFD wil receive advice on how to follow a low FODMAP diet. They wil follow this diet for 4 weeks. Thereafter they receive advice on how to reintroduce high FODMAPs again.
Control group. Participants follow their regular gluten-free diet (GFD), with no changes to their diet. They wil receive the same dietary advice as the LFD-group after the 4-week study.
Outcomes
Primary Outcome Measures
Change in gastrointestinal symptoms
Measured by score in gastrointestinal symptom rating scale for irritable bowel syndrome (GSRS-IBS). The scoring is based on a 7-grade Likert scale in which 1 point indicates no symptoms and 7 points the most severe gastrointestinal symptoms. The total score in the gastrointestinal symptom rating scale for irritable bowel syndrome is calculated as a mean value of all 13 items. The maximum score is 91 and the minimum score is 13. A higher score means more severe symptoms. A score higher than 1 standard deviation (SD, 0.66 points) compared to the control mean are considered to have increased gastrointestinal symptoms.
Secondary Outcome Measures
Changes in biomarkers like faecal microbiota
Altered faecal microbiota diversity, measured as a change in diversity and/or abundance or strains from baseline and after 4 weeks on a low FODMAP diet.
Quality of Life in patients with coeliac disease: Short form- 36 (SF-36)
Changes in short form-36 (SF-36) as a measure of quality of life. SF-36 covers four physical health perceptions (physical functioning, role limitations because of physical health problems, bodily pain, and general health) and four mental health concepts (vitality, social functioning, role limitations because of personal or emotional problems, and mental health perceptions). Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The range of score is 0 to 100, where a higher score means better quality of life and the lower the score the more disability. A total score for mental health and physical health is calculated as an average of the subscales, with a range from 0 to 100. Here also the higher the score the better quality of life. The standardized combined scores in several populations have a mean of 50 and standard deviation 10. The scoring wil be performed as in the SF-36 scoring manual.
Full Information
NCT ID
NCT03678935
First Posted
September 17, 2018
Last Updated
July 10, 2020
Sponsor
Oslo University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03678935
Brief Title
Effect of FODMAP Restriction on Persistent GI-symptoms in Coeliac Patients
Official Title
Effect of Fermentable Oligo-, di-, and Monosaccharides and Polyols (FODMAP) Restriction on Persistent GI-symptoms in Coeliac Patients
Study Type
Interventional
2. Study Status
Record Verification Date
July 2020
Overall Recruitment Status
Unknown status
Study Start Date
October 1, 2018 (Actual)
Primary Completion Date
June 1, 2021 (Anticipated)
Study Completion Date
October 1, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Oslo University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The first aim of the study is to investigate the prevalence of persistent gastrointestinal symptoms and compliance with gluten-free diet and the intake of FODMAP in adult celiac patients.
A web-based survey wil be performed and thereafter a randomized controlled trial to test the effect of a FODMAP reduction in patients with celiac disease with irritable bowel-like symptoms.
Detailed Description
Effect of FODMAP reduction in patients with celiac disease. Celiac disease is an immune-mediated disease that causes damage to the intestines. The condition affects 1-2% of the population, and the incidence is increasing. Treatment with gluten-free diet usually produces good results, yet there are many patients who have persistent gastrointestinal symptoms. Studies indicate that this applies to as many as 20%, but the situation in Norway in unknown. Nor is it known why somebody has persistent gastro- intestinal complaints. It may be due to difficulty following the diet or what is called irritable bowel syndrome (IBS), which is a fairly common condition in the population.
It has been shown that people with IBS can benefit from a diet with reduced FODMAP content. The term FODMAP is an acronym for: Fermentable Oligo, Di-, Monosaccharides and Polyols. It is a type of carbohydrate that is not absorbed in the large intestine, but continues to the colon where they are fermented by the bacteria. Example of foods with a high content of FODMAP is wheat, onion, garlic, parsley, apples, pears, mango, beans, honey and milk. It is not known whether celiac patients with persistent symptoms will have the beneficial effect of low FODMAP diet.
In this study, investigators want to study the prevalence of persistent gastrointestinal symptoms and compliance with gluten-free diet and the intake of FODMAP in adult celiac patients. Members of the Norwegian coeliac organization will be invited to participate in the study. A web-based questionnaire is used to make it easy for members to respond.
Participants who report persistent gastrointestinal intestinal symptoms will then be invited to a randomized and controlled study. They will be divided into two groups where one group will be advised to reduce the intake of FODMAP and the other group will be advised to follow a strict gluten-free diet. Participants will record stomach and intestinal complaints before and after four weeks with study sites. Investigators will find out whether there is a difference between gastric and intestinal complaints between the two groups. Blood- and feces samples will also be collected.
The results will provide new knowledge about how to adapt dietary advice to celiac patients with persistent gastrointestinal complaints, and hopefully help them to a better quality of life.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Celiac Disease, Irritable Bowel Syndrome, Diet Modification, Gluten Sensitivity
Keywords
Celiac disease, Irritable bowel syndrome
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The intervention group receives advice on following the low-FODMAP diet, and the control group follows their regular gluten free diet.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
80 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Low FODMAP diet (LFD)
Arm Type
Active Comparator
Arm Description
The LFD wil receive advice on how to follow a low FODMAP diet. They wil follow this diet for 4 weeks. Thereafter they receive advice on how to reintroduce high FODMAPs again.
Arm Title
Control
Arm Type
No Intervention
Arm Description
Control group. Participants follow their regular gluten-free diet (GFD), with no changes to their diet. They wil receive the same dietary advice as the LFD-group after the 4-week study.
Intervention Type
Other
Intervention Name(s)
Low FODMAP diet
Intervention Description
The intervention group follows the low FODMAP diet for 4 weeks.
Primary Outcome Measure Information:
Title
Change in gastrointestinal symptoms
Description
Measured by score in gastrointestinal symptom rating scale for irritable bowel syndrome (GSRS-IBS). The scoring is based on a 7-grade Likert scale in which 1 point indicates no symptoms and 7 points the most severe gastrointestinal symptoms. The total score in the gastrointestinal symptom rating scale for irritable bowel syndrome is calculated as a mean value of all 13 items. The maximum score is 91 and the minimum score is 13. A higher score means more severe symptoms. A score higher than 1 standard deviation (SD, 0.66 points) compared to the control mean are considered to have increased gastrointestinal symptoms.
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Changes in biomarkers like faecal microbiota
Description
Altered faecal microbiota diversity, measured as a change in diversity and/or abundance or strains from baseline and after 4 weeks on a low FODMAP diet.
Time Frame
4 weeks
Title
Quality of Life in patients with coeliac disease: Short form- 36 (SF-36)
Description
Changes in short form-36 (SF-36) as a measure of quality of life. SF-36 covers four physical health perceptions (physical functioning, role limitations because of physical health problems, bodily pain, and general health) and four mental health concepts (vitality, social functioning, role limitations because of personal or emotional problems, and mental health perceptions). Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The range of score is 0 to 100, where a higher score means better quality of life and the lower the score the more disability. A total score for mental health and physical health is calculated as an average of the subscales, with a range from 0 to 100. Here also the higher the score the better quality of life. The standardized combined scores in several populations have a mean of 50 and standard deviation 10. The scoring wil be performed as in the SF-36 scoring manual.
Time Frame
4 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Coeliac disease
Adherent to GFD for at least 12 months
Strictly adherent to GFD
Normal coeliac disease (CD) serology and duodenal biopsy (Marsh 0-1)
Persistent GI-symptoms defined by GSRS-IBS score of 30 or more
Living less than 2 hour from study centre
Exclusion Criteria:
Pregnancy or lactating women
Use of immunomodulating drugs in the last 3 months
Use of anti-inflammatory drugs in the last 3 months
Use of antacid drugs in the last 2 months
Ongoing infection (mild infection such as upper airway infection is ok)
Other chronical bowel disorder (except for IBS)
Previous tried the LFD with guidance of a dietician
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Knut Lundin, Professor
Organizational Affiliation
Oslo University hospital and University of Oslo
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rikshospitalet-Radiumhospitalet HF, Oslo University Hospital
City
Oslo
State/Province
Postboks PB 4950 Nydalen
ZIP/Postal Code
0424
Country
Norway
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
35051648
Citation
van Megen F, Skodje GI, Lergenmuller S, Zuhlke S, Aabakken L, Veierod MB, Henriksen C, Lundin KEA. A Low FODMAP Diet Reduces Symptoms in Treated Celiac Patients With Ongoing Symptoms-A Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2022 Oct;20(10):2258-2266.e3. doi: 10.1016/j.cgh.2022.01.011. Epub 2022 Jan 17.
Results Reference
derived
Learn more about this trial
Effect of FODMAP Restriction on Persistent GI-symptoms in Coeliac Patients
We'll reach out to this number within 24 hrs